Small molecule · Inhibitor of topoisomerase II (TOP2A) · developed by CNS Pharmaceuticals
Berubicin is a 4'-O-benzylated anthracycline derivative that intercalates into DNA and inhibits topoisomerase II, blocking DNA replication and repair as well as RNA and protein synthesis. Unlike other anthracyclines, it crosses the blood-brain barrier and resists P-glycoprotein/MRP1-mediated efflux. It is studied in glioblastoma multiforme.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04762069 | Phase 2 | Glioblastoma Multiforme, Adult | Active not recruiting | CNSP |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Glioblastoma Multiforme, Adult
Updated Oct 3, 2026. Something wrong or missing? Report it on the CNSP page.
See CNSP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CNSP catalysts and pipeline →